Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David G. Loughhead is active.

Publication


Featured researches published by David G. Loughhead.


Tetrahedron Letters | 1997

The Florisil® catalyzed [1,3]-sigmatropic shift of allyl phenyl ethers — An entryway into novel mycophenolic acid analogues

Francisco Xavier Talamas; David Bernard Smith; Alicia Cervantes; Fidencio Franco; Serena T. Cutler; David G. Loughhead; David J. Morgans; Robert James Weikert

Abstract Florisil ® was found to be effective in promoting the [1,3]-sigmatropic shift of mycophenolic acid related allyl phenyl ethers. Several novel mycophenolic acid analogues were thus prepared. Through a crossover experiment using two deuterated analogues of the model system, the reaction was shown to be intramolecular.


Bioorganic & Medicinal Chemistry Letters | 2010

Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.

David Mark Rotstein; Chris Richard Melville; Fernando Padilla; Dick Cournoyer; Eun Kyung Lee; Remy Lemoine; Ann C. Petersen; Lina Setti; Jutta Wanner; Lijing Chen; Lubov Filonova; David G. Loughhead; Jason Manka; Xiao-Fa Lin; Shelley K. Gleason; Surya Sankuratri; Changhua Ji; André deRosier; Marianna Dioszegi; Gabrielle Heilek; Andreas Jekle; Pamela Berry; Cheng-I. Mau; Paul Weller

Starting with a high-throughput screening lead, a novel series of CCR5 antagonists was developed utilizing an information-based approach. Improvement of pharmacokinetic properties for the series was pursued by SAR exploration of the lead template. The synthesis, SAR and biological profiles of the series are described.


Journal of Medicinal Chemistry | 2017

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld; Timothy D. Owens; Erik Verner; Eleni Venetsanakos; J. Michael Bradshaw; Vernon T. Phan; Danny Tam; Kwan Leung; Jin Shu; Jacob LaStant; David G. Loughhead; Tony Ton; Dane Karr; Mary E. Gerritsen; David Michael Goldstein; Jens Oliver Funk

Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to develop an irreversible covalent inhibitor of FGFR1-4 for use in oncology indications. An irreversible covalent binding mechanism imparts many desirable pharmacological benefits including high potency, selectivity, and prolonged target inhibition. Herein we report the structure-based design, medicinal chemistry optimization, and unique ADME assays of our irreversible covalent drug discovery program which culminated in the discovery of compound 34 (PRN1371), a highly selective and potent FGFR1-4 inhibitor.


Tetrahedron Letters | 1988

Unusual reductions induced by formic acid

David G. Loughhead

Abstract Treatment of xanthene carbinol 1a or xanthenylidene derivative 2a with refluxing formic acid unexpectedly gave dihydro compound 3a . Thioxanthene and acridine carbinols 1b and 1c and acridinylidene derivative 2c were also partially reduced when treated with formic acid.


Archive | 1997

Treatment of neuropathic pain

Jacob Berger; Lee A. Flippin; John Cureton Hunter; David G. Loughhead; Robert James Weikert


Journal of Medicinal Chemistry | 1996

Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase by nuclear variants of mycophenolic acid.

Peter H. Nelson; Stephen F. Carr; Bruce H. Devens; Elsie M. Eugui; Fidencio Franco; Carlos Gonzalez; Ronald Charles Hawley; David G. Loughhead; David J. Milan; Eva Papp; John W. Patterson; Sussan Rouhafza; Eric Brian Sjogren; David Bernard Smith; Rebecca A. Stephenson; Francisco Xavier Talamas; Ann-Marie Waltos; Robert James Weikert; John C. Wu


Archive | 1995

5-substituted derivatives of mycophenolic acid

David J. Morgans; David Bernard Smith; Francisco Xavier Talamas; Dean R. Artis; Alicia Cervantes; Todd R. Elworthy; Mario Fernandez; Fidencio Franco; Ronald Charles Hawley; Teresa Lara; David G. Loughhead; Peter H. Nelson; John W. Patterson; John C. Rohloff; Eric Brian Sjogren; Alejandra Trejo; Ann Marie Waltos; Robert James Weikert


Journal of Organic Chemistry | 1996

ASYMMETRIC SYNTHESIS AND STEREOCHEMICAL ASSIGNMENT OF RS-97613, A POTENT IMMUNOSUPPRESSIVE AND ANTIINFLAMMATORY AGENT

David Bernard Smith; Ann Marie Waltos; David G. Loughhead; Robert James Weikert; David J. Morgans; John C. Rohloff; John O. Link; Rong-rong Zhu


Journal of Medicinal Chemistry | 1991

Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole

Robert James Weikert; Stanford Bingham; Mark A. Emanuel; Elizabeth B. Fraser-Smith; David G. Loughhead; Peter H. Nelson; Anthony L. Poulton


Journal of Organic Chemistry | 1999

SYNTHESIS OF MEXILETINE STEREOISOMERS AND RELATED COMPOUNDS VIA SNAR NUCLEOPHILIC SUBSTITUTION OF A CR(CO)3-COMPLEXED AROMATIC FLUORIDE

David G. Loughhead; Lee A. Flippin; Robert James Weikert

Collaboration


Dive into the David G. Loughhead's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lee A. Flippin

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge